Cosmologists have spent decades trying to pin down exactly how fast the universe is flying apart and whether that rate is ...

Genetic algorithms (GAs) mimic natural selection to solve complex optimization problems across engineering, AI, and science. By evolving a population of solutions through selection, crossover, and ...

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial Overall survival (OS) should be evaluated in ...

Abstract: Many evolutionary algorithms have been developed by the researcher. Genetic algorithms and memetic algorithms are most commonly used by researchers to solve various optimization problems.

Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...

Judging by market expectations and policymakers' comments, there's virtually no chance the Fed will change its benchmark interest rate when its meeting concludes Wednesday. The near-term stance likely ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

In patients with HNF1A-related maturity-onset diabetes of the young (HNF1A-MODY), 4 weeks of treatment with the SGLT2 inhibitor empagliflozin, along with other glucose-lowering therapies, improved ...

Motor speed control is crucial for maintaining the normal operation of motors. In view of the limitations of current motor speed control methods, such as high parameter dependence, obvious control ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.